Please upgrade your browser.
Phase 1 Cancer Trial for Altiratinib (DCC-2701) MET/TIE2/VEGFR/TRK Kinase Inhibitor for Solid Tumors
Deciphera Pharmaceuticals a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701). The Phase 1 trial will evaluate the safety tolerability and initial efficacy of altiratinib in cancer patients with solid tumors. Altiratinib has been shown to exhibit high potency and selectivity for inhibiting MET TIE2 VEGFR2 and TRK kinases in preclinical studies. A companion diagnostic assay will also be co-developed during the course of clinical studies.
Abstracts mentioning renal cell carcinoma (kidney cancer) from the 2014 ASCO Annual Meeting in Chicago.
Cell-Cycle Gene Test Shows Early Promise in Clear Cell RCC - See more at: http://www.onclive.com/conference-coverage/aua-2014/Cell-Cycle-Gene-Test-Shows-Early-Promise-in-Clear-Cell-RCC#sthash.DhoRovxs
A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology...
Nearly half of respondents report losing access to doctors, hospitals, and treatments
Prof Swanton discusses his presentation at the recent European International Kidney Cancer Symposium sponsored by US based Kidney Cancer Association
Madison-based biotech firm Centrose received a six-month $224,734 grant...
Patients with metastatic renal cell carcinoma face a poor prognosis; currently, 30% of patients already have metastatic disease at the time of diagnosis, according to national data.
"The strategy of repurposing drugs that are currently being used for other indications is of significant interest to the medical community..."
Prof Wood talks to ecancertv at the EIKCS conference about the different surgical strategies available for approaching renal cell carcinoma with inferior vena cava invasion and their outcomes post-surgery.
Results for nivolumab and Yervoy® (ipilimumab) as a combination regimen in three tumor types to be presented, including melanoma and the first findings in non-small cell lung cancer and renal cell carcinoma.
|Powered by NeonCRM|